WXXWY News and Press, Wuxi Biologics Cayman Inc ADR From 11/22/19

DUNDALK, Ireland , Nov. 22, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development, and manufacturing, announced that its subsidiary WuXi Vaccines, en...

SHANGHAI , Nov. 19, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today congratulates its partner Tychan on successfu...

Deals and Financings Ascentage Pharma of Suzhou completed a $53 million Hong Kong IPO, pricing the offering at the top end of the indicated range with a market capitalization of almost $890 million. The company is developing therapeutics for cancer based on its expertise in protein-protein i...

Wuxi Biologics ADR ( OTCPK:WXXWY ): 1H Non-GAAP EPS of RMB0.39; GAAP EPS of RMB0.34. More news on: Wuxi Biologics (Cayman) Inc ADR, Earnings news and commentary, , Read more ...

WUXI, China , June 21, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it planned to expand the new state-of-...

SHANGHAI , May 21, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has entered into a strategic part...

Deals and Financings MGI Tech Company, a Shenzhen maker of gene sequencing machines, announced it closed its first funding round with more than $200 million. MGI is a subsidiary of BGI, China's largest sequencing services provider. Founded in 2016, MGI is dedicated to offering a China altern...

CHENGDU, China , May 16, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that the construction of a new 1.3 millio...

Deals and Financings Hutchison China MediTech (Chi-Med) [AIM:HCM] (HCM) filed to IPO on the Hong Kong Exchange, following listings in London and on NASDAQ, where it has a market capitalization of over $4 billion (see story ). In September 2018, Chi-Med was approved to launch fruquintinib in...

SHANGHAI , April 17, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that its Drug Substance (DS) and Drug P...